Johnson and Johnson and Xencor reach CD28 dual anti-development joint...

On December 7, Xencor announced a partnership agreement with Johnson and Johnson for the development of ® dual-specific antibodies targeting CD28.
deal is expected to be completed by the end of the year.
terms of the agreement, Xencor will use its XmAb dual-specific Fc technology platform to build a dual-specific antibody that Janssen specifies to target tumor CD28.
CD28 is a T-cell immunostitulation complex and an unrealized target for prostate cancer, for which potential treatments for prostate cancer can be developed.
Johnson and Johnson will have exclusive global licensing rights for the full life cycle of preclinical research, clinical development, regulatory and commercialization activities for drug candidates.
In addition, both Xencor and Johnson and Johnson can select drug candidates and their own pipeline portfolios from each other's product pipelines, including Johnson and Johnson's commercialized drugs, during the non-registered clinical study phase to develop potential combination therapies for prostate cancer.
Xencor will receive $50 million in advance payments and development, regulatory, sales milestone payments, and double-digit sales share based on net sales.
after clinically conceptual validation of dual-specific drug candidates, Xencor has the option to provide 20% of development costs in the United States and to be responsible for up to 30% of the specific work.
Xencor will be eligible for milestone payments and sales share based on net sales of less than double digits to 15%.
Sil Dahiyat, President of
Xencor, said, "Our XmAb dual-specific Fc domain is able to create a wide range of multisexual antibodies and protein structures, such as our new twin-specific antibodies that target CD28.
these antibodies stimulate T cells together in a tumor-targeted manner and can be used in collaboration with checkpoint inhibitor therapy and other tumor-targeted drugs, such as CD3 dual-specific antibodies, to enhance anti-tumor activity.
addition, we have developed two companies' anti-prostate cancer portfolio therapies, leveraging Xencor's extensive clinical product line and Johnson and Johnson's leading portfolio of prostate cancer treatments.
"